Faslodex First-Line Study Suggests Potential Inferiority To Tamoxifen – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Results of a trial assessing first-line use of AstraZeneca’s Faslodex in advanced breast cancer suggest that the agent "may not be equally efficacious as tamoxifen in the first-line setting," FDA said in review documents.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class